Drug intelligence / Profile preview

аАКДС-Геп В+Hib

Development stage
Unknown
Lead developer
SPA Microgen
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

аАКДС-Геп В+Hib (also known as АКДС-Геп В + Hib) is an approved pentavalent combination vaccine developed by Immunopreparat (a subsidiary of Microgen). It is indicated for the active immunization of children against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) infection. The vaccine is formulated as a suspension for intramuscular injection, consisting of an acellular pertussis component (which reduces reactogenicity compared to whole-cell vaccines), diphtheria and tetanus toxoids, recombinant hepatitis B surface antigen (HBsAg), and a synthetic conjugated Hib capsular polysaccharide (polyribosylribitol phosphate) component. It is adsorbed onto aluminum hydroxide as an adjuvant to enhance the protective humoral immune response against all five targeted pathogens.

Brand names
аАКДС-Геп B+HibаАКДС-Геп В+HibАКДС-Геп B + HibАКДС-Геп В + Hib
Other names
aAKDS-Hep B + HibaAKDS-Hep B+Hibdiphtheria, tetanus, pertussis (acellular), hepatitis B and Haemophilus influenzae type b vaccinediphtheria-haemophilus influenzae B-pertussis-tetanus-hepatitis B vaccine
02

Targets

HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)PRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)

Beyond the preview

Go deeper on аАКДС-Геп В+Hib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on аАКДС-Геп В+Hib.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call